Introduction
Recommendations for diagnosis and management of malignant diseases are organized by international expert panels. For example, the first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults were published in 2010 (1) and recently revised in 2017 (2) . Based on the most recent DNA-sequencing results, such as those derived from The Cancer Genome Atlas (TCGA), AML can be subdivided into multiple subclasses (3) (4) (5) (6) (7) (8) (9) (10) (11) . While subclassification is already based on genomic information, according to the ELN recommendations primary and differential diagnosis still relies on classical approaches including assessment of morphology, immunophenotyping, cytochemistry and cytogenetics (2) . This is surprising considering that in a pioneering study almost two decades ago Golub et al. demonstrated that AML could be identified by combining gene expression profiling (GEP) and computational class prediction (12) . Admittedly, this initial study was very small and without a true validation cohort, but subsequent work promised to fundamentally change primary and differential diagnosis of AML by assessing the transcriptome (13) (14) (15) (16) (17) . Furthermore, it had been suggested that GEP could be utilized to define leukemia subtypes and derive useful predictive gene signatures (18, 19) . A decade later, the International Microarray Innovations in Leukemia Study Group even proposed GEP by microarray analysis to be a robust technology for the diagnosis of hematologic malignancies with high accuracy (20) . The utility of GEP by RNA-sequencing has been also demonstrated for other tumor entities for example breast cancer (21) (22) (23) , bladder or lung cancer (24, 25) . Also, in AML research large RNA-seq datasets have been described in the meantime (26) (27) (28) (29) (30) . However, despite these promising results and data, GEP did not translate into clinical practice for AML diagnostics.
In parallel, a series of advances in machine learning (ML) and computational statistics have transformed our understanding of prediction using high-dimensional data. A variety of approaches are now an established part of the toolkit and for some models (including sparse linear and generalized linear models), there is a rich mathematical theory concerning their performance in the high-dimensional setting (31) . In a nutshell, the body of empirical and theoretical research has shown that learning predictive models over large numbers of variables is often feasible and remarkably effective. In applied machine learning, there has been a deepening understanding of practical issues, e.g. relating to the transferability of predictions across contexts (32) , that is very relevant to the clinical setting.
Based on these developments in the data sciences and the increasing availability of GEP data derived from peripheral blood including AML, we sought to re-assess the potential for translation of transcriptomic data into AML diagnostics. To this end, we built the probably largest reference blood GEP dataset comprising 105 individual studies with in total more than 12,000 patient samples. We applied high-dimensional machine learning approaches to build genome-wide predictors in an unbiased, entirely data-driven manner, and tested predictive accuracy in held-out data. We carried out extensive tests designed to address specific concerns relevant to practical use, including the case of transferring predictive models between entirely disjoint studies (that could be subject to batch effects or other unwanted variation) and even between transcriptomic platforms. Our results show that combining machine learning and blood transcriptomics can yield highly effective and robust classifiers. This supports the notion that GEP should be considered for AML diagnostics and tested directly against currently recommended classical approaches.
Results

Establishment of a unique GEP dataset for classifier development
We hypothesized that the determination and comprehensive evaluation of GEP-based AML classifiers requires large datasets, should include samples from many sources to mimic the situation in real-world deployment and should include several technical platforms to better understand their influence on classifier performance. To achieve these goals, we wanted to include the largest number of peripheral blood mononuclear cells (PBMC) or bone marrow samples possible and therefore systematically searched the National Center for Biotechnology Gene Expression Omnibus (GEO) database for PBMC and bone marrow studies ( Fig. 1A) . We identified 153,922 datasets, of which 111,632 also contained human samples. To include only whole sample series and to avoid duplicate samples, we filtered for GEO series (GSE) and excluded so-called super series, which resulted in 6800 studies. Of those, 5320 contained bone marrow and PBMC samples, of which 2715 were human studies. We then focused the analysis on studies with samples analyzed on one of three platforms including the HG-U133A microarray, the HG-U133 2.0 microarray and Illumina RNA-seq. Next, duplicated samples and studies working with pre-filtered cell subsets were excluded. This study search strategy resulted in 105 studies with a total of 12,029 samples ( Fig 1) including 2,500 samples assessed by HG-U133A microarray (Dataset 1), 8,348 samples by HG-U133 2.0 microarray (Dataset 2) and 1,181 samples by RNA-seq (Dataset 3). In total, the dataset contained 4,145 AML samples of diverse disease subtypes and 7,884 other samples derived from healthy controls (n=904), patients with acute lymphocytic leukemia (ALL, n=3,466), chronic myeloid leukemia (CML, n=162), chronic lymphocytic leukemia (CLL, n=770), myelodysplastic syndrome (MDS, n=267) and other non-leukemic diseases (n=2,312) ( Fig. 1B , Fig S1) . Unless otherwise noted, all samples derived from AML patients are referred to as cases and non-AML samples as controls. We additionally considered differential diagnosis, in which case the controls comprised non-AML leukemias. According to the three platform types, the whole sample cohort was divided into three datasets referred to as datasets 1, 2 and 3 (Table S1, Fig. S1 ).
Effective AML classification using high-dimensional models
Here, we sought to assess classification of AML vs non-AML. Microarray data were RMA normalized while RNA-seq data was normalized as implemented in the R package DESeq2 (33) . For further analysis and better comparison between the different datasets, we trimmed the data to 12,708 genes identified within all datasets ( Fig. 2A ). The size of the test set was 20% of the total sample size and random sampling of training and test sets was repeated 100 times. As main performance metrics, we considered (held-out) accuracy, sensitivity and specificity. Classification was performed using l1-regularized logistic regression (the lasso; see also below).
First, we included all non-AML samples, including healthy controls and non-leukemic diseases, among the controls ( Fig. 2B , D, F, light blue lines). The goal was to classify unseen samples as AML or control. To understand how much data is needed in this setting, we plotted learning curves showing the test set accuracy as a function of training sample size ntrain. For each gene expression platform, this was done by randomly subsampling ntrain samples and testing on held-out test data with fixed sample size ntest (as shown). We see that prediction in this setting is already highly effective with a small number of training samples, although accuracy still increases with increasing ntrain (note that the total number of samples and hence range of ntrain differs by platform).
In many clinical settings, the control group does not contain healthy controls, but rather related diseases. To test effectiveness in a differential diagnosis setting, we repeated the experiments but with controls sampled only from other leukemic diseases, such as ALL, CLL, CML and MDS ( Fig.  2C , E, Fig. S2-4 ). We observed similar prediction results, which indicated that prediction accuracy is not only due to large differences between AML and non-leukemic conditions. For diagnostic utility, the positive predictive value (PPV; the probability of disease given a positive test result) is an important quantity. The PPV depends not only on sensitivity and specificity but also on prevalence, as it is harder to achieve a high PPV for a condition that is rare in the population of interest. Although we found high accuracy, sensitivity and specificity already at moderate ntrain, depending on the use case, this could still imply that large training sample sizes would be useful to reach higher PPVs. For example, the predictive gains in increasing ntrain from the lowest to highest values indicated in Fig 2D, which is for the dataset with largest total sample size, correspond to a doubling of PPV from ~20% to ~40% at an assumed prevalence of 1% ( Fig 2G) . This illustrates the fact that although after a certain point increasing ntrain tends to increase accuracy only slowly, the gains, even if small in absolute terms, can be highly relevant with respect to PPV in low-prevalence settings.
In additional experiments we considered performance of nine different classification methods (Figs S2-4). We could predict AML with high accuracy with all tested classification algorithms on microarray platforms ( Fig. S2 & S3 ). For RNA-seq data, the lasso and random forests were able to predict with high sensitivity and specificity ( Fig. S4 ). Lasso-type methods have several advantages, including extensive theoretical support and interpretability, so we focused on these as our main predictive tool. Deep neural networks provided comparable prediction performance to the lasso (data not shown), but we preferred the latter in this setting again due to interpretability, since the lasso provides explicit variable selection, facilitating model interpretation.
Assessing the effect of cross-study-variation on predictive performance
Microarray data and data generated by high-throughput sequencing are both known to be susceptible to batch effects (34) . More generally, diverse study-specific effects and sources of study-to-study variation can pose problems in the context of predictive tests for clinical applications. Predictors that perform well within one study may perform worse when applied to data from new studies (35) with implications for practical generalizability.
The results above spanned data from multiple heterogeneous studies. Provided training and test data are sampled in the same way, such heterogeneity does not necessarily pose problems for classification, as evidenced above. However, if the training and test data are from entirely different sites/studies (rather than randomly sampled from a shared pool), then the impact of batch/study effects may be more serious. We took advantage of the large number of studies in our dataset to sample training and testing sets in such a way that they were mutually disjoint with respect to studies. That is, any study that was at all represented in the training set was entirely absent from the test set and vice versa and we use the term cross-study to refer to this strictly disjoint case. Results are shown in Fig 2B, D,F (dark blue lines). As expected, performance was worse in the cross-study setting than under entirely random sampling (light blue lines). However, in the dataset with the largest sample size (dataset 2, platform HG-U133 2.0; Fig. 2D ) we see that the performance in the cross-study case gradually catches up to the random sampling case with only a small gap at the largest ntrain. The other two datasets have smaller total sample sizes so never reach comparable training sample sizes. Note that we did not carry out any batch effect removal using tools such as SVA (36) or RUV (37) and in that sense our results are conservative. Despite the availability of these and other tools for batch effect correction, it is difficult to be fully assured of the removal of unwanted variation in practice. Our intention here was not to remove betweenstudy variation but rather to (conservatively) quantify its effects on accuracy.
Due to the large number of studies included in our analysis, we were able to carry out an entirely disjoint cross-study analysis also for the differential diagnosis case. These results are shown in Fig  2C ,E (dark blue lines; cross-study sampling for differential diagnosis was not possible using dataset 3 due to lack of samples, see Fig. S1 ) and are broadly similar, also across different classification algorithms (S5-S7).
Translation of classifiers across technical platforms
Over the long term, clinical pipelines must cope with changes in technological platforms. It is therefore relevant to understand to what extent predictors can generalize not just between studies, but between different platforms. In other words: is it possible to take a model learned on data from platform A and deploy it using unseen data from platform B? To address this question, we constructed AML vs non-AML training and test sets in a cross-platform manner, i.e. training on one platform and testing on another (Fig. 3A) . That is, a model was learned using data from one platform and then this model -used "as is", with no further fine tuning -was used to make predictions using expression data from a different platform. We see that classification accuracy varies greatly. Classifiers that were trained on HG-U133 A (dataset 1) work well when tested using data generated with the more advanced microarray HG-U133 2.0 (dataset 2) ( Fig. 3B ) and models trained on HG-U133 2.0 data can predict well using RNA-seq data (dataset 3) ( Fig. 3D ). However, models trained naively on HG-U133 A data cannot predict using RNA-seq data (Fig. 3F ).
To explore the utility of simple transformations in this context, we then performed a rank transformation to normality on all datasets. This is among the simplest and best known data transformations and has previously been shown to increase the performance of prognostic gene expression signatures and can even outperform more complex variance-stabilizing approaches (38) . With this approach, we reached very good overall performance across all platforms under study (Fig 3 C , E, H). Note that the transformation is simply applied to each dataset independently and could be easily deployed in any practical use-case without any need for prior input into e.g. cross-platform designs such as inclusion of control samples.
Predictive signatures and AML biology
The predictive models derived from the lasso and used above are sparse in the sense that they automatically select a small number of genes to drive the prediction. The genes are selected in a unified global analysis, rather than by differential expression on a gene-by-gene basis. From a statistical point of view, global sparsity patterns for prediction and gene-by-gene differential expression are different criteria. Furthermore, a good set of genes for prediction need not be mechanistic (in the sense of constituting causal drivers of the disease state). We therefore sought to understand the relationship between differential expression (DE), known mechanisms and predictive gene signatures.
Using dataset 2 (the largest dataset) we compared DE and the sparse predictive models. We performed DE analysis using the whole dataset and compared the results with the set of genes in the lasso model ("lasso genes") based on the same data ( Fig 4A) . 506 genes were differentially expressed ("DE genes"), of which 26 were associated with the disease ontology term or KEGG pathway for AML ("AML-related genes"). Of the 141 Lasso genes, 7 genes were leukemia-related and 46 were DE genes, meaning that many of the lasso genes were not differentially expressed, as clearly seen when overlaying the lasso gene selection on a volcano plot ( Fig 4A) . This underlines the fact that differential expression and predictive value in a signature sense are different criteria.
Next, we extended this analysis to focus on DE and lasso genes whose selection was robust to data subsampling. This was done by subsampling half the dataset randomly 100 times and in each such subsample carrying out the full DE and lasso analyses. For the lasso this type of approach has been studied under the name stability selection (39) . DE and lasso genes were then scored according to the frequency with which they appeared among the 100 rounds of selection ( Fig 4B) . Thus, an inclusion score of 100% for a DE gene means that the gene is selected as differentially expressed in all 100 iterations and similarly for the lasso genes. In total, 669 genes passed the DE cutoffs in a least 50% of the iterations, while 80 genes were called in at least 50% of the iterations by the lasso-model ( Fig. 4B ). Of these genes, 35 were called according to both criteria. These results show that even among the genes that are included in the lasso models with high frequency (i.e. those genes that are robustly selected for prediction), many are not differentially expressed. To look at the relationship between differentially expressed genes and prediction from another perspective, we entirely excluded the 1000 most differentially expressed genes, and re-learned predictive signatures. Classification accuracy was essentially unaffected, demonstrating the robustness of high-dimensional predictive analyses to the absence of even the highest-ranked DE genes.
To better understand the biological relevance of these 35 genes for AML, we visualized the top ranked genes over all 8,348 samples within the dataset by hierarchical clustering of z-transformed expression values (Fig. 4C ). We identified one distinct cluster of genes with the majority of genes being elevated in AML compared to other leukemias and non-leukemic samples (cluster 1, n=29). While we identified several well-known AML-related genes (gene name in red color) such as the KIT Proto-Oncogene Receptor Tyrosine Kinase (KIT) (40-42), RUNX2 (43), and FLT3 (44, 45) in this cluster, many genes have not yet been linked to AML biology and, although not the focus of the present paper, further study of these genes may be interesting from a mechanistic point of view. Within the other cluster (cluster 2, n=6 genes), genes had reduced expression values in AML compared to other leukemias and two of these genes have been linked to other types of leukemias (gene names in orange color).
Numerous transcriptional regulators (TRs) were among the top 35 ranked genes, including one HOX transcription factor. To further elucidate this finding, we performed a co-expression network analysis based on all TRs (Fig. 4D ) and used infomap clustering to further explore the network (Fig. 4E ). Three central clusters were defined that were further subdivided into smaller clusters. To find out whether clusters of co-expressed TRs were specific for distinct disease types, we visualized the fold change of the mean expression of every group versus the mean over all samples (group fold change) for each cluster and each disease in a heatmap (Fig. 4E) , which indicated panleukemia clusters as well as cluster specific for AML and the closely related MDS (dark blue cluster, n = 26 genes and middle blue cluster, n = 17 genes). Interestingly, one of those AMLrelated clusters was particularly populated by HOX TFs (Fig. 4D ) of which HOXA9 has been linked to poor AML prognosis (46) (47) (48) . To determine a potential master regulator, we performed TF motif enrichment analysis on this cluster and identified HOXA9 as one of the most prominent candidate master regulators of this AML-associated TF cluster.
Discussion
Despite the pioneering studies by Golub and others (12) (13) (14) (15) (16) (17) suggesting high potential value of GEP for AML diagnosis and differential diagnosis, the most current recommendations for this disease still center on classical approaches including assessment of morphology, immunophenotyping, cytochemistry, and cytogenetics (2). By making use of more than 12,000 samples from more than 100 individual studies, we provided evidence that the combination of large GEP data with statistical and machine learning approaches allows for the development of robust disease classifiers. Such classifiers could be used for diagnosis and differential diagnosis of this deadly disease. Considering the increased utilization of whole genome and transcriptome sequencing in the management of cancer patients, we propose that clinical application of GEPand machine learning-based classifiers for diagnosis including differential diagnosis -instead of, or alongside, the more classical techniques -needs to be re-evaluated. This is in line with previous suggestions by the International Microarray Innovations in Leukemia Study Group (20) . We suggest that similar analyses may be useful for other diseases, when analyzing whole blood or PBMC-derived gene expression profiles.
We analyzed the largest collection of data so far in AML transcriptomics with the aim of understanding and addressing bottlenecks in the way of clinical deployment of gene expressionbased machine learning tools for diagnosis. We considered a range of practical concerns, including differential diagnosis, cross-study issues and prediction across different technological platforms. We found that highly accurate prediction is possible in all scenarios considered. From a technical perspective, all the approaches we employed could be deployed at scale. We found also that in most cases good test results were achieved with relatively few training samples. The exception was for cross-study prediction, where a larger number of samples was needed to match the predictive performance seen in the (easier) random sampling case.
Site-and study-specific effects may be relevant for clinical applications. This is due to the fact that a classifier once learned might be deployed in a range of new settings (sites, regions) that could lead in a number of ways to unwanted variation. If training and test sets are very different, this can impact performance. Nevertheless, we saw that given sufficiently large training samples, crossstudy prediction was effective. This suggests that while standardizing data collection as much as possible is of course desirable, given strong enough signals it may be possible to deliver useful predictions even in the face of unwanted and perhaps unknown variability. Nevertheless, in clinical applications of predictive models it will be important to continually track performance even after deployment.
All our models were learned in an unbiased manner, directly from the full transcriptome data with no prior biological knowledge or any pre-selection of genes. We showed that genes relevant for prediction were often not differentially expressed and that prediction was robust to removal of highly differentially expressed genes. These observations illustrate two points of relevance to clinical applications. First, that for prediction it can be more fruitful to consider signatures derived in data-driven, genome-wide fashion than to think in terms of single genes or differential expression. Second, that high-dimensional analyses, although complex relative to more classical methods, can be highly predictive as well as robust to the presence or absence of specific genes. Taken together, our results underline the immense value of making GEP data publicly available, allowing for new and large-scale multi-study analyses. Further, we believe that the application of statistical and machine learning approaches based on sequencing data to identify gene signatures for certain diseases such as AML will become part of recommendations for diagnosis and management of AML. We envision that combining whole genome and transcriptome analysis based on machine learning algorithms will ultimately allow diagnosis, differential diagnosis, subclassification and outcome prediction in an integrated fashion.
Methods
Review and selection of gene expression data
All data sets published in the National Center for Biotechnology Information Gene Expression Omnibus (GEO, Barrett et al., 2012) on 20 September 2017 were reviewed for inclusion in the present study. Basic criteria for inclusion were the cell type under study (human peripheral blood mononuclear cells (PMBCs) and/or bone marrow samples) as well as the species (Homo sapiens). Furthermore, we excluded GEO SuperSeries to avoid duplicated samples (Table S1 ). We filtered the datasets for data generated with Affymetrix HG-U133 A microarrays, Affymetrix HG-U133 2.0 microarrays and high-throughput RNA sequencing (RNA-seq) and excluded studies with very small sample sizes (< 50 samples for microarray and < 10 samples for RNA-seq data). We then applied a disease-specific search, in which we filtered for acute myeloid leukemia, other leukemia and healthy or non-leukemia-related samples.
The results of this search strategy were then internally reviewed and data were excluded based on the following criteria: (i) exclusion of duplicated samples, (ii) exclusion of studies that sorted single cell types (e.g. T cells or B cells) prior to gene expression profiling, (iii) exclusion of studies with inaccessible data. Other than that, no studies were excluded from our analysis. In addition, we included one unpublished dataset (in dataset 1). The above steps gave rise to the data referred to above as dataset 1 (Affymetrix HG-U133 A microarrays), dataset 2 (Affymetrix HG-U133 2.0 microarrays) and dataset 3 (RNA-seq).
Pre-processing
All raw data files were downloaded from GEO. For normalization, we considered all platforms independently, meaning that normalization was performed separately for the samples in dataset 1, 2 and 3, respectively. Microarray data (datasets 1 and 2) were normalized using the robust multichip average (RMA) expression measures (49) , as implemented in the R package affy (50) . RNA-seq data (dataset 3) was normalized with the R package DeSeq2 using standard parameters (33) . In order to keep the datasets comparable, we filtered the data for genes annotated in all three datasets, which resulted in 12.708 genes. No filtering of low-expressed genes was performed. All scripts used in this study for pre-processing are provided as a docker container on GitHub (51) .
Prediction
Prior to classification, data sets were split into non-overlapping training and test data. All classification tasks were performed in the programming language R (52). All main results were obtained using l1-penalized logistic regression using the package glmnet (53) . Non-zero coefficients were extracted for feature ranking (Figure 4 ). The sparsity parameter was set using 10-fold cross-validation (using training set data only). To assess predictive performance, accuracy, sensitivity and specificity were calculated as well as positive predictive value (PPV) under several prevalence scenarios. For assessing the performance of support vector machines (SVMs), we used the R package e1071 for SVMs (linear, radial, polynomial and sigmoid kernels) (54) . The R package randomForest was used for random forest classification (55) . K nearest neighbors classification was done using the knn function implemented in the class package in R (56) . Linear discriminant analysis was performed with the lda function implemented in the R package MASS (56) . For RNA-seq data, features with zero variance were excluded for LDA. Prediction analysis of microarrays was done with the pamr package (57) . Neural networks were built using Keras with a Tensorflow backend (10 layers, ~7×10 6 parameters). Unless otherwise noted, default settings were used for tuning parameters as implemented in the respective packages.
Differential expression analysis
For differential expression analysis of dataset 2 the R package limma was used (58) . A linear model was fit on the data with inclusion of the study as a factor. Differentially expressed genes were called using an FDR-corrected p-value < 0.05 and a minimum fold change of +/-2. For the permutation-based approach, 4174 samples were randomly drawn 100 times from the dataset. In each subset, DE genes were called as before, but without correcting for any batch in the model. The number of times each gene was called was summed up over all 100 permutations. Genes were ranked according to their overall DE count.
In addition to that a l1-penalized logistic regression was performed using the package glmnet (53) on the whole dataset and on each of the permutations. Genes were called to be of predictive importance if features had non-zero coefficients. The number of times each feature was of predictive importance was summed up, which resulted in a feature ranking of all "lasso genes".
Hierarchical Clustering 35 genes which had a stability of > 50% over 100 permutations were visualized using the R package pheatmap (59) (Fig. 4B) . The data was z-scaled and columns clustered according to Euclidean distance. Rows were ordered according to diseases. Two gene clusters were visualized.
Co-expression network analysis of transcriptional regulators All 12.708 genes of dataset 2 were filtered for transcriptional regulators (TRs), resulting in 750 present TRs. Pearson correlation between genes was calculated using the rcorr function of the R package Hmisc (60) . 613 TRs with Pearson Correlation Coefficient > 0.509 and a p-value < 0.05 were visualized in a network with force-directed layout using Cytoscape. To define clusters within the network, all nodes were subjected to infomap community finding clustering (61) using the R package igraph (62) . Genes were clustered 1000 times and genes were allocated to the most frequent cluster. Genes that were advised to at least 20 different clusters were not assigned to any cluster and colored in white. This strategy resulted in 13 clusters, which were mapped on the network.
Hierarchical clustering of co-expressed TRs
To find out whether clusters of co-expressed TRs were specific for distinct disease types, we plotted the mean fold change of all genes in one cluster vs. the corresponding overall mean in a heatmap. This was done for each disease individually and then visualized in one network graph using the R package pheatmap (56) .
Prediction of transcriptional regulators
To predict master regulators for genes of the AML-specific cluster, the 17 genes of the AMLspecific cluster (n= 17 genes) were tested for enriched known transcription factor binding motifs using the function findMotifs.pl from the software package HOMER v4.9.1 (63) with standard settings and the promoter set "human". The top ten best matches of enriched motifs were checked for presence in the co-expression network of TFs and visualized in the network. D   E   C   HBG1  BSG  NME7  GOLIM4  PLAGL1  RUNX2  ACTA2  NR1H3  DNM1  FLT3  ANKRD28  CHRFAM7A   TPSB2  PLTP  MICALL2  MEST  TFPI  NPR3  KIT  DEPTOR  ARL4A  CXCL2  PLD1  JAG1  APOC4−APOC2   NRIP3  HOXB5  HOMER3  ADGRA2  CDC14B   WLS  TLE1  SDHAP1  MYLK 
